AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1106810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuterol hydrochloride 2 mg
Number of subjects: 12
Study 1106810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuterol hydrochloride 4 mg
Number of subjects: 12
Study 1106810 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 5 mg
Number of subjects: 12
Study 31996581 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal open hemorrhoidectomy
Number of subjects: 98
Study 31996581 — intervention group
Group type: COMPARATOR
Intervention: Transanal hemorrhoidal dearterialization
Number of subjects: 98
Study 30350096 — intervention group
Group type: EXPERIMENTAL
Intervention: Transumbilical incision
Number of subjects: 102
Study 25533591 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic continuous positive airway pressure (CPAP) for 8 weeks
Number of subjects: 29
Study 25533591 — intervention group
Group type: COMPARATOR
Intervention: Sham continuous positive airway pressure for 8 weeks
Number of subjects: 29
Study 23220074 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA 250 mg/day
Number of subjects: 60
Study 23220074 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA 500 mg/day
Number of subjects: 60
Study 23220074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21304095 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 8696
Study 21304095 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 8696
Study 21304095 — intervention group
Group type: EXPERIMENTAL
Intervention: black race
Number of subjects: 8696
Study 19255065 — intervention group
Group type: EXPERIMENTAL
Intervention: PURPLE materials
Number of subjects: 1279
Study 19255065 — intervention group
Group type: COMPARATOR
Intervention: Control materials
Number of subjects: 1279
Study 16762668 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasch mathematical model (RMM) applied to examination 1 with up to 20% of student responses randomly missing.
Number of subjects: 100
Study 16762668 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasch mathematical model (RMM) applied to examination 1 with up to 40% of items being dropped.
Number of subjects: 100
Study 16762668 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasch mathematical model (RMM) applied to combined examinations 1 and 2.
Number of subjects: 100
Study 15016284 — intervention group
Group type: EXPERIMENTAL
Intervention: Odor imagery
Number of subjects: 72
Study 15016284 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual imagery
Number of subjects: 72
Study 15016284 — intervention group
Group type: COMPARATOR
Intervention: No-imagery control
Number of subjects: 72
Study 11728613 — intervention group
Group type: EXPERIMENTAL
Intervention: Amineptine
Number of subjects: 28
Study 11728613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9598014 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glycolic acid cream
Number of subjects: 75
Study 9598014 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 75
Study 7930717 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DR+ CD38+ CD8+ cell population
Number of subjects: 0
Study 7930717 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable CD4+ cell levels
Number of subjects: 0
Study 7930717 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term survivors (seropositive for 9 years, > 800 CD4+ cells/mm3)
Number of subjects: 0
Study 7930717 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective elevation of HLA-DR+ CD38- CD8+ cells
Number of subjects: 0
Study 3078907 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 32
Study 3078907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 29099396 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic distal pancreatectomy (LDP)
Number of subjects: 3701
Study 29099396 — intervention group
Group type: COMPARATOR
Intervention: Open distal pancreatectomy (ODP)
Number of subjects: 3701
Study 26443707 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia-hyperoxia training combined with light exercise (O2 at 10% and O2 at 30%, 6-8 cycles, total time 45 min-1 h, three times a week for 4 weeks)
Number of subjects: 15
Study 26443707 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia-hyperoxia training combined with light exercise
Number of subjects: 15
Study 26443707 — intervention group
Group type: COMPARATOR
Intervention: Control group (19 healthy athletes following usual training schedule)
Number of subjects: 15
Study 24846511 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 61
Study 24846511 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 61
Study 23772156 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose breath test positive (LBT (+)) IBS patients
Number of subjects: 68
Study 23772156 — intervention group
Group type: EXPERIMENTAL
Intervention: Methane producers
Number of subjects: 68
Study 23772156 — intervention group
Group type: EXPERIMENTAL
Intervention: LBT (+) IBS patients
Number of subjects: 68
Study 23772156 — intervention group
Group type: COMPARATOR
Intervention: LBT (−) IBS patients
Number of subjects: 68
Study 23772156 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 68
Study 22256334 — intervention group
Group type: EXPERIMENTAL
Intervention: 62% ethyl alcohol in emollient gel applied by male partners each morning and before and after sexual intercourse
Number of subjects: 223
Study 22256334 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 223
Study 19501210 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA-SC
Number of subjects: 266
Study 19501210 — intervention group
Group type: COMPARATOR
Intervention: DMPA-IM
Number of subjects: 266
Study 16584059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 16584059 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg FA
Number of subjects: 61
Study 16584059 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg FA
Number of subjects: 61
Study 16584059 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg FA
Number of subjects: 61
Study 14667178 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg)
Number of subjects: 14
Study 14667178 — intervention group
Group type: COMPARATOR
Intervention: Control (no orlistat)
Number of subjects: 14
Study 10801249 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated methylnaltrexone (6.4 mg/kg)
Number of subjects: 12
Study 10801249 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated methylnaltrexone (3.2 mg/kg)
Number of subjects: 12
Study 10801249 — intervention group
Group type: COMPARATOR
Intervention: Morphine (control)
Number of subjects: 12
Study 10801249 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated methylnaltrexone (3.2 mg/kg) after morphine
Number of subjects: 12
Study 8618436 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alone in early CP (Group 1: 160 patients)
Number of subjects: 238
Study 8618436 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alone in late CP (Group 2: 31 patients)
Number of subjects: 238
Study 8618436 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN before and after autologous stem cell transplantation (ASCT) (Group 3: 23 patients)
Number of subjects: 238
Study 8618436 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN after ASCT (Group 4: 24 patients)
Number of subjects: 238
Study 8618436 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders to IFN
Number of subjects: 238
Study 8618436 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders to IFN
Number of subjects: 238
Study 1473672 — intervention group
Group type: EXPERIMENTAL
Intervention: Air contrast barium enema performed the same day as incomplete colonoscopy
Number of subjects: 38
Study 1473672 — intervention group
Group type: COMPARATOR
Intervention: Air contrast barium enema performed on a different day from incomplete colonoscopy
Number of subjects: 38
Study 6392159 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 51
Study 6392159 — intervention group
Group type: COMPARATOR
Intervention: Renografin 60
Number of subjects: 51
Study 31631761 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth peer-support programme delivered by videoconferencing for 6 weeks
Number of subjects: 69
Study 31631761 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth peer-support programme delivered by videoconferencing
Number of subjects: 69
Study 29221645 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management programme (intervention)
Number of subjects: 306
Study 29221645 — intervention group
Group type: COMPARATOR
Intervention: Best-practice care by guidelines (control)
Number of subjects: 306
Study 27619832 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic dilation
Number of subjects: 50
Study 27619832 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Heller myotomy with partial fundoplication
Number of subjects: 50
Study 27619832 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 24793176 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly intervention group (GIM): instructions on fall prevention and healthy exercises with monthly refresher sessions.
Number of subjects: 249
Study 24793176 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly intervention group (GIT): same beginning intervention with refresher sessions every three months.
Number of subjects: 249
Study 24793176 — intervention group
Group type: COMPARATOR
Intervention: Control group (GC): same beginning intervention but no refresher sessions.
Number of subjects: 249
Study 24793176 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 249
Study 22537767 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (1mg/day)
Number of subjects: 150
Study 22537767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol (2 mg/day)
Number of subjects: 150
Study 22537767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol (2 mg/day) + MPA (5mg/day)
Number of subjects: 150
Study 22537767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 22537767 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol-only therapy
Number of subjects: 150
Study 22537767 — intervention group
Group type: EXPERIMENTAL
Intervention: All hormone regimens
Number of subjects: 150
Study 22537767 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol-only regimen
Number of subjects: 150
Study 20666584 — intervention group
Group type: EXPERIMENTAL
Intervention: tgAAC09 (3 x 10(10) DRP)
Number of subjects: 91
Study 20666584 — intervention group
Group type: EXPERIMENTAL
Intervention: tgAAC09 (3 x 10(11) DRP)
Number of subjects: 91
Study 20666584 — intervention group
Group type: EXPERIMENTAL
Intervention: tgAAC09 (3 x 10(12) DRP)
Number of subjects: 91
Study 20666584 — intervention group
Group type: EXPERIMENTAL
Intervention: tgAAC09 (2 doses)
Number of subjects: 91
Study 20666584 — intervention group
Group type: EXPERIMENTAL
Intervention: tgAAC09 (boosting at 6 months)
Number of subjects: 91
Study 17346816 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (4 mg intravenous bolus followed by 6 mg/h continuous infusion for 24 h)
Number of subjects: 49
Study 17346816 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nicorandil)
Number of subjects: 49
Study 11298145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime with acetazolamide (subgroup A)
Number of subjects: 188
Study 11298145 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime without acetazolamide (subgroup B)
Number of subjects: 188
Study 11298145 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime with acetazolamide (subgroup A)
Number of subjects: 188
Study 11298145 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime without acetazolamide (subgroup B)
Number of subjects: 188
Study 11298145 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam with acetazolamide (subgroup A)
Number of subjects: 188
Study 11298145 — intervention group
Group type: COMPARATOR
Intervention: Aztreonam without acetazolamide (subgroup B)
Number of subjects: 188
Study 11298145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone with acetazolamide (subgroup A)
Number of subjects: 188
Study 11298145 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone without acetazolamide (subgroup B)
Number of subjects: 188
Study 9213790 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction of slow‐acting antirheumatic drugs (SAARDs)
Number of subjects: 304
Study 9213790 — intervention group
Group type: COMPARATOR
Intervention: Delayed introduction of slow‐acting antirheumatic drugs (SAARDs)
Number of subjects: 304
Study 9213790 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (early SAARD and delayed SAARD)
Number of subjects: 304
Study 7963710 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy
Number of subjects: 102
Study 7963710 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 treatment
Number of subjects: 102
Study 7963710 — intervention group
Group type: EXPERIMENTAL
Intervention: bDNA assay
Number of subjects: 102
Study 3315588 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC) administered as an intravenous bolus of 30U
Number of subjects: 16
Study 3315588 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary streptokinase (250,000U)
Number of subjects: 16
Study 31261549 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized graded lumbar stabilization exercise (IGLSE)
Number of subjects: 48
Study 31261549 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise (WE)
Number of subjects: 48
Study 31261549 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization exercise (SE)
Number of subjects: 48
Study 31261549 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization with walking exercise (SWE)
Number of subjects: 48
Study 28330385 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health workers intervention
Number of subjects: 180
Study 28330385 — intervention group
Group type: COMPARATOR
Intervention: Attentional control
Number of subjects: 180
Study 28330385 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 25868758 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser flap creation
Number of subjects: 21
Study 25868758 — intervention group
Group type: COMPARATOR
Intervention: Mechanical microkeratome flap creation
Number of subjects: 21
Study 23584130 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum adalimumab concentration at week 4 of CLASSIC I
Number of subjects: 275
Study 23584130 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum adalimumab concentration at weeks 4, 24, and 56 of CLASSIC II
Number of subjects: 275
Study 23584130 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Crohn's Disease Activity Index, baseline C-reactive protein, and adalimumab concentrations
Number of subjects: 275
Study 23584130 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curves
Number of subjects: 275
Study 21204686 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Direct Treatment Intervention (BDTI)
Number of subjects: 192
Study 21204686 — intervention group
Group type: COMPARATOR
Intervention: Telephone Quitline (TQ)
Number of subjects: 192
Study 18050385 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 500 mg
Number of subjects: 367
Study 18050385 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 1000 mg
Number of subjects: 367
Study 18050385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study 16924028 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with early HD
Number of subjects: 13
Study 16924028 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 13
Study 12939099 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical care with physical therapy
Number of subjects: 681
Study 12939099 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical care without physical therapy
Number of subjects: 681
Study 12939099 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care with physical modalities
Number of subjects: 681
Study 12939099 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care without physical modalities
Number of subjects: 681
Study 10716674 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan, 6 mg subcutaneously
Number of subjects: 0
Study 10716674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9374124 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/d fish oil
Number of subjects: 58
Study 9374124 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/d fish oil
Number of subjects: 58
Study 9374124 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g/d fish oil
Number of subjects: 58
Study 9374124 — intervention group
Group type: COMPARATOR
Intervention: 0 g/d fish oil (control)
Number of subjects: 58
Study 1347210 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing Retraining and Cognitive Restructuring
Number of subjects: 0
Study 1347210 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Self-Exposure in vivo
Number of subjects: 0
Study 1347210 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Breathing Retraining and Cognitive Restructuring with Self-Exposure
Number of subjects: 0
Study 1347210 — intervention group
Group type: EXPERIMENTAL
Intervention: Further treatment during follow-up period
Number of subjects: 0
Study 1347210 — intervention group
Group type: COMPARATOR
Intervention: Demographic variables, pre- and posttest scores, medication use
Number of subjects: 0
Study 30165804 — intervention group
Group type: EXPERIMENTAL
Intervention: Single needle arthrocentesis with distention of the upper compartment of the TMJ (A1)
Number of subjects: 26
Study 30165804 — intervention group
Group type: COMPARATOR
Intervention: Conventional arthrocentesis with 2 needles (A2)
Number of subjects: 26
Study 29185901 — intervention group
Group type: EXPERIMENTAL
Intervention: Central reader PET/CT interpretation
Number of subjects: 356
Study 29185901 — intervention group
Group type: COMPARATOR
Intervention: Local institutional review
Number of subjects: 356
Study 29185901 — intervention group
Group type: EXPERIMENTAL
Intervention: Central reader AUC
Number of subjects: 356
Study 29185901 — intervention group
Group type: COMPARATOR
Intervention: Local institutional AUC
Number of subjects: 356
Study 27046570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoslide (VR game)
Number of subjects: 20
Study 27046570 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 25193003 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (TX)
Number of subjects: 42
Study 25193003 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WLC)
Number of subjects: 42
Study 23732372 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberil® (weight-loss supplement derived from potato)
Number of subjects: 0
Study 23732372 — intervention group
Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 0
Study 20163990 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta and high-dose daclizumab (2 mg/kg every 2 weeks)
Number of subjects: 230
Study 20163990 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta and low-dose daclizumab (1 mg/kg every 4 weeks)
Number of subjects: 230
Study 20163990 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta and placebo
Number of subjects: 230
Study 18335727 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfilled resin composite (Filtek A110) with a one‐bottle bonding system (Single Bond)
Number of subjects: 96
Study 18335727 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacid‐modified resin composite (compomer) (Dyract AP) with a filled one‐bottle bonding system (Prime & Bond NT) using 36% phosphoric acid pretreatment
Number of subjects: 96
Study 18335727 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacid‐modified resin composite (compomer) (Dyract AP) with a filled one‐bottle bonding system (Prime & Bond NT) using a non‐rinse conditioner (NRC) and a self‐priming pretreatment
Number of subjects: 96
Study 18335727 — intervention group
Group type: COMPARATOR
Intervention: All groups (Microfilled resin composite and both compomers)
Number of subjects: 96
Study 16272001 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S (n = 12) - responded to reversible sentences in a computerized game
Number of subjects: 33
Study 16272001 — intervention group
Group type: EXPERIMENTAL
Intervention: Group M (n = 12) - same stimuli acoustically modified
Number of subjects: 33
Study 16272001 — intervention group
Group type: COMPARATOR
Intervention: Group U (n = 9) - untrained control group
Number of subjects: 33
Study 14614782 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse abdominal incision
Number of subjects: 172
Study 14614782 — intervention group
Group type: COMPARATOR
Intervention: Vertical abdominal incision
Number of subjects: 172
Study 11938858 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvia miltiorrhiza compound injection (SMCI) 200 mg/kg intravenously before operation and at rewarming
Number of subjects: 20
Study 11938858 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 20
Study 9358725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 26
Study 1302811 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoconazole nitrate (1% cream, Travogen)
Number of subjects: 40
Study 1302811 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole (1% cream, Canestan)
Number of subjects: 40
Study 3891821 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (240 mg/day and 120 mg/day)
Number of subjects: 126
Study 3891821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 3891821 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (high dose 240 mg/day)
Number of subjects: 126
Study 3891821 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 126
Study 30741790 — intervention group
Group type: EXPERIMENTAL
Intervention: PLLA injections
Number of subjects: 40
Study 30741790 — intervention group
Group type: COMPARATOR
Intervention: Saline injections (control group)
Number of subjects: 40